Post marketing surveillance (PMS) in Japan for soft tissue sarcoma (STS) patients treated with pazopanib

被引：2
|
作者：
Kawai, A. [1 ]
Araki, N. [2 ]
Ando, Y. [3 ]
Nakano, K. [4 ]
Machida, M. [5 ]
Yoshida, P. [6 ]
机构：
[1] Natl Canc Ctr, Div Musculoskeletal Oncol, Tokyo, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Orthopaed Surg, Osaka, Japan
[3] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Med Oncol, Tokyo, Japan
[5] Novartis Pharma KK, Oncol Med Affairs Dept, Tokyo, Japan
[6] GlaxoSmithKline KK, Safety & PMS Dept, Dev & Med Affairs Div, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31911-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3438
引用
收藏
页码：S701 / S701
页数：1
相关论文
共 50 条
  • [1] Prognostic factors of soft tissue sarcoma (STS) treated with pazopanib from Nishinomiya Sarcoma Cohort Study (NSCS)
    Narahara, H.
    Tanaka, E.
    Morimoto, M.
    Morita, K.
    Fukushima, J.
    Iio, S.
    Yasunaga, Y.
    Inui, Y.
    Kawata, S.
    Takahashi, K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan
    Teshima, Yasutomo
    Nomura, Satoshi
    Fukasawa, Nobuaki
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (04) : 612 - 621
  • [3] Prognostic Importance of Inflammatory Indexes in Patients Treated by Pazopanib for Soft Tissue Sarcoma
    Koseci, Tolga
    Haksoyler, Veysel
    Olgun, Polat
    Ata, Serdar
    Nayir, Erdinc
    Duman, Berna B.
    Cil, Timucin
    [J]. CLINICAL LABORATORY, 2022, 68 (02) : 340 - 352
  • [4] Pazopanib vs pazopanib/gemcitabine in refractory soft tissue sarcoma: The AIO-STS-009-trial
    Ruessel, J.
    Lindner, L.
    Reichard, P.
    Heissner, K.
    Kopp, H. -G
    Kessler, T.
    Mayer-Steinacker, R.
    Egerer, G.
    Crysandt, M.
    Kasper, B.
    Niederwieser, D.
    Kunitz, A.
    Eigendorff, E.
    Steighardt, J.
    Cygon, F.
    Meinert, F.
    Stein, A.
    Schmoll, H. -J
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 306 - 306
  • [5] Hypertension (HTN) as a biomarker of efficacy in pazopanib-treated patients (pts) with advanced non-adipocytic soft tissue sarcoma (STS)
    Duffaud, F.
    Sleijfer, S.
    Litiere, S.
    Ray-Coquard, I.
    Le Cesne, A.
    Papal, Z.
    Judson, I.
    Hodge, R.
    Marreaud, S.
    Van der Graaf, W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S887 - S887
  • [6] Pazopanib for soft tissue sarcoma (STS) in the first-line setting with denosumab.
    Narahara, Hiroyuki
    Yasuda, Kayo
    Morita, Kaori
    Matsumoto, Hitoshi
    Yasunaga, Yuichi
    Inui, Yoshiaki
    Kawata, Sumio
    Takahashi, Katsuhito
    Teraoka, Satoshi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Post-marketing Surveillance (PMS) of all Patients Treated with Irinotecan in Japan: Clinical Experience and ADR Profile of 13 935 Patients
    Tadokoro, Jun-ichi
    Kakihata, Koji
    Shimazaki, Minoru
    Shiozawa, Tomoo
    Masatani, Shuji
    Yamaguchi, Fumie
    Sakata, Yuh
    Ariyoshi, Yutaka
    Fukuoka, Masahiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (09) : 1101 - 1111
  • [8] Pazopanib In Advanced Soft Tissue Sarcoma
    Deeks, Emma D.
    [J]. DRUGS, 2012, 72 (16) : 2129 - 2140
  • [9] PAZOPANIB FOR ADVANCED SOFT TISSUE SARCOMA
    Takamori, H.
    Karasuno, T.
    Nishiura, N.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [10] Pazopanib in the treatment of soft tissue sarcoma
    Schoeffski, Patrick
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (06) : 711 - 723
12345